OPTIMIZERx Corporation Executes New Terms to Securities Redemption Option Agreement With Vicis
03 Januar 2014 - 4:09PM
Marketwired
OPTIMIZERx Corporation Executes New Terms to Securities Redemption
Option Agreement With Vicis
ROCHESTER, MI--(Marketwired - Jan 3, 2014) - OPTIMIZERx Corp.
(OTCQB: OPRX) announced on January 2, 2014, we executed an
Amendment to the Securities Redemption Option Agreement with
Vicis Capital Master Fund ("Vicis") to, among other things, extend
the term of our option to March 31, 2014 and reduce the price of
the option from nine million dollars ($9,000,000) to six million
dollars ($6,000,000). The shares and derivative securities include
the Series A Convertible Preferred Stock, Series B Convertible
Preferred Stock, Common Stock, and warrants to purchase shares of
Series A Convertible Preferred Stock and Series B Convertible
Preferred Stock held by Vicis.
The Company's Chief Executive Officer and Chairman Mr. David
Harrell added, "We are very pleased to have negotiated this
extension at more favorable terms and am confident we will swiftly
complete this transaction per the high interest expressed from both
strategic and financial investors in our proven innovation, growth
and performance -- as well as OPTIMIZERx's unique position to serve
leading pharmaceutical and healthcare companies. Additionally, this
provides an ideal opportunity to improve and clean up our capital
structure."
About OPTIMIZERx Corp.: OPTIMIZERx Corp. (OTCQB: OPRX) provides
unique consumer and physician platforms to help patients better
afford and comply with their medicines and healthcare products,
while offering pharmaceutical and healthcare companies effective
ways to expand patient awareness, access and adherence to their
medications. For more information, please go to
www.optimizerxcorp.com.
For further Investor Information on OPTIMIZERx Corp., please
contact: Christopher Schreiber, Taglich Brothers, at
917-445-6207
'SAFE HARBOR' This press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended and such section 21E of the Securities Act
of 1934, amended. These forward-looking statements should not be
used to make an investment decision. The words 'estimate,'
'possible' and 'seeking' and similar expressions identify
forward-looking statements, which speak only as to the date the
statement was made. The company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
Christopher Schreiber Taglich Brothers 917-445-6207
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024